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Abstract
Background: Diabetic polyneuropathy (DPN) is the most common and early developing complication of diabetes
mellitus, and the key contributor for foot ulcers development, with no specific therapies available.
Different studies have shown that mesenchymal stem cell (MSC) administration is able to ameliorate DPN; however,
limited cell survival and safety reasons hinder its transfer from bench to bedside. MSCs secrete a broad range of
antioxidant, neuroprotective, angiogenic, and immunomodulatory factors (known as conditioned medium), which
are all decreased in the peripheral nerves of diabetic patients. Furthermore, the abundance of these factors can be
boosted in vitro by incubating MSCs with a preconditioning stimulus, enhancing their therapeutic efficacy. We
hypothesize that systemic administration of conditioned medium derived from preconditioned MSCs could reverse
DPN and prevent foot ulcer formation in a mouse model of type II diabetes mellitus.
Methods: Diabetic BKS db/db mice were treated with systemic administration of conditioned medium derived from
preconditioned human MSCs; conditioned medium derived from non-preconditioned MSCs or vehicle after
behavioral signs of DPN was already present. Conditioned medium or vehicle administration was repeated every
2 weeks for a total of four administrations, and several functional and structural parameters characteristic of DPN
were evaluated. Finally, a wound was made in the dorsal surface of both feet, and the kinetics of wound closure,
re-epithelialization, angiogenesis, and cell proliferation were evaluated.
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Results: Our molecular, electrophysiological, and histological analysis demonstrated that the administration of
conditioned medium derived from non-preconditioned MSCs or from preconditioned MSCs to diabetic BKS db/db
mice strongly reverts the established DPN, improving thermal and mechanical sensitivity, restoring intraepidermal
nerve fiber density, reducing neuron and Schwann cell apoptosis, improving angiogenesis, and reducing chronic
inflammation of peripheral nerves. Furthermore, DPN reversion induced by conditioned medium administration
enhances the wound healing process by accelerating wound closure, improving the re-epithelialization of the
injured skin and increasing blood vessels in the wound bed in a skin injury model that mimics a foot ulcer.
Conclusions: Studies conducted indicate that MSC-conditioned medium administration could be a novel cell-free
therapeutic approach to reverse the initial stages of DPN, avoiding the risk of lower limb amputation triggered by
foot ulcer formation and accelerating the wound healing process in case it occurs.
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Background
Diabetic polyneuropathy (DPN) is the most common
and early developing complication of diabetes mellitus
(DM), affecting up to 60% of type I and type II DM pa-
tients [1]. It is characterized by progressive distal-to-
proximal degeneration of peripheral nerves, resulting in
sensory loss, chronic pain, and recurrent ulcerations [2, 3].
These ulcerations do not proceed through the normal
wound healing process and often develop gangrenous in-
fections, leading to the amputation of the affected limb
[2]. Thus, DPN is responsible for 20% of the hospitaliza-
tions of DM patients and is the second leading cause of
amputation worldwide [4].
Despite the continuing and increasing incidence of
DPN, nowadays, there is no specific treatment able to
stop DPN progression and prevent the formation of foot
ulcers (FU). Furthermore, the palliative drugs commonly
used, such as antiepileptics, antidepressants, and opioids,
are symptomatic treatments with untoward side effects;
thus, they are not recommended as long-term treat-
ments [5]. The main difficulty in generating a compre-
hensive treatment for DPN is due to its highly complex
and multifactorial etiology [6]. Strong evidence shows
that exacerbated glucose flux leads to the over-activation
of different pathways for its metabolism. The common
factor of these pathways is the production of high levels
of reactive oxygen species (ROS) in the mitochondria,
turning oxidative stress into a central player in the onset
and progression of DPN [7]. Increased ROS levels in-
duce (i) apoptosis of neurons and Schwann cells in dor-
sal root ganglia (DRG) and peripheral nerves, with a
concomitant reduction in the local levels of neuropro-
tective factors; (ii) reduction of the local blood flow to
nerve fibers and a marked decline in the angiogenic
process; and (iii) a chronic pro-inflammatory process [6,
8]. Therefore, the reduced expression of neuroprotective,
angiogenic, and anti-inflammatory factors in peripheral
nerves plays a crucial role in the development and pro-
gression of DPN [6, 8]. In FU in diabetic patients, the
detailed mechanisms of impaired wound healing are not
completely understood. However, it is clear that the de-
generation of nerve fibers and the reduced blood flow
greatly contribute to this process [2].
Based on its various causative pathways, a number of
experimental strategies to treat DPN have focused on
the systemic administration of antioxidant [9], anti-
inflammatory [10], neuroprotective [11], and angiogenic
factors [12]. However, while most of these strategies
have shown promising results in preclinical animal stud-
ies, the transfer of these procedures to clinical practice
has been unsuccessful [8, 13], which is mainly related to
the fact that the pathogenesis of DPN is multifactorial.
Therefore, a single molecule-based therapy (mono-target
therapy) is unlikely to be effective.
Stem cell-based therapies represent promising thera-
peutic approaches for the treatment of complex diseases
like DPN, since unlike conventional pharmacological
treatments, stem cells act through multiple mechanisms
(multi-target therapy) [14]. Among the different types of
adult stem cells, adipose tissue-derived mesenchymal stem
cells (AD-MSCs) have several advantages that make them
attractive candidates for the treatment of DPN, since they
(i) can be easily isolated from the waste material of cos-
metic liposuction and highly expanded in vitro, (ii) secrete
several antioxidant molecules [15], and (iii) produce high
levels of trophic factors including neuroprotective, angio-
genic, and anti-inflammatory factors [16, 17].
In this sense, it has been reported that the intramuscu-
lar injection of MSCs into animal models of DPN in-
duced the recovery of motor and sensory nerve
conduction velocities, the recovery of the normal ultra-
structure of peripheral nerves, the induction of an in-
creased blood flow to damaged nerves, and a reduction
in the hypoalgesia to thermal and mechanical stimula-
tion [18–21]. In these reports, the therapeutic effects
were correlated with an increase in the levels of several
neuroprotective, angiogenic, and anti-inflammatory fac-
tors in the nerves, with no differentiation of MSCs into
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neurons or Schwann cells [18–20]. However, the clinical
use of MSCs is still reduced, due to several safety and
technical limitations associated with the administration
of living cells [22–24].
In the case of FU, it has also been reported that the
administration of MSCs directly onto the wounds improved
wound closure by promoting skin re-epithelialization and
improving the angiogenic process [25, 26]. However, the
primary limitation of this therapeutic strategy is that since
DPN persists, FU are constantly occurring in diabetic pa-
tients. Therefore, this complex procedure needs to be re-
peated whenever the patient has a new ulcer.
The main therapeutic mechanism associated with
MSC administration is the paracrine secretion of a broad
spectrum of biologically active factors and extracellular
vesicles, generally referred to as MSC-conditioned
medium [27]. Furthermore, it has been reported that the
abundance of these molecules can be regulated in vitro
by incubating the cells with a preconditioning stimulus
[28], enriching the composition of the conditioned
medium with molecules relevant for the treatment of a spe-
cific pathology. Thus, MSC-derived conditioned medium
could be used as a biodrug, replacing the need to adminis-
ter living cells. Furthermore, this treatment can be repeated
over time since it does not generate immunological reac-
tions [29].
Recently, we reported that the preconditioning of AD-
MSC by in vitro incubation with the hypoxic mimetic
agent deferoxamine (DFX) induced a significant increase
in the secretion of potent antioxidant, neuroprotective,
angiogenic, and anti-inflammatory factors compared to
non-preconditioned cells [30]. Additionally, conditioned
medium obtained from DFX preconditioned cells showed
greater neuroprotective effects compared with the condi-
tioned medium obtained from non-preconditioned MSCs,
when evaluated in an in vitro model of DPN [30].
In the present study, we evaluated whether the systemic
administration of conditioned medium derived from DFX-
preconditioned AD-MSCs or from non-preconditioned
AD-MSCs was able to reverse several functional and struc-
tural alterations characteristic of DPN and to prevent the
formation of FU, in BKS db/db mice, one of the most ro-
bust animal models of DPN [31–33]. We demonstrated
that systemic administrations of conditioned medium de-
rived from non-preconditioned MSCs or from DFX-
preconditioned MSCs strongly revert the established DPN,
improving thermal and mechanical sensitivity, restoring
normal skin innervation, reducing sensory neuron and
Schwann cell apoptosis, improving angiogenesis, and
reducing chronic inflammation. Furthermore, DPN re-
version induced by conditioned medium administra-
tion enhances the wound healing process; thus, this
therapy could also be effective in preventing FU for-
mation in diabetic patients.
Methods
Animals
Transgenic mice (BKS.Cg-m+/+Leprdb/J) that spontan-
eously develop T2DM were purchased from Jackson La-
boratories (Bar Harbor, USA). Female diabetic (db/db)
and non-diabetic (db/+) mice were housed at constant
temperature and humidity, with a 12-h light/dark cycle
and unrestricted access to standard chow and water. All
animal protocols were approved by the Ethics Commit-
tee of Universidad del Desarrollo.
Isolation, expansion, and characterization of AD-MSCs
Human AD-MSCs were isolated from fresh subcutaneous
adipose tissue samples (abdominal region) obtained from
liposuction aspirates of four healthy female donors under-
going cosmetic liposuction at Clínica Alemana, Chile, as
previously described [30]. Written informed consent was
obtained for all samples and protocols used were approved
by the Ethics Committee of Universidad del Desarrollo.
After two subcultures, adherent cells were characterized
according to their adipogenic and osteogenic differenti-
ation potential, by the presence of putative MSC markers
(CD29, CD13, CD105, CD73, and CD90) and the absence
of markers characteristic of other cell lineages (CD235a,
CD31, and CD45) as previously described [30].
Preconditioning of AD-MSC with DFX and conditioned
medium purification
AD-MSCs (passage 3) were plated at a density of
7000 cells/cm2 and cultured in minimum essential medium
(α-MEM) (Gibco, New Zealand) supplemented with 10%
fetal bovine serum (FBS) (Gibco, New Zeeland) and 0.16
mg/ml gentamicin (Sanderson Laboratory, Chile) at 37°C in
a 5% CO2 atmosphere. When cells reached 70% confluence,
plates were rinsed three times with PBS and cells were in-
cubated for 48 h in α-MEM without FBS supplemented
with 400 μM DFX (Sigma-Aldrich, USA) (preconditioned
AD-MSCs) or with saline (vehicle) as non-preconditioned
AD-MSCs. After the incubation with DFX or saline, the
MSC-conditioned media were obtained by harvesting the
culture media. The media were centrifuged at 400g for 10
min to remove whole cells, and the supernatant was centri-
fuged again at 5000 g for 20min to remove cell debris as
previously described [30]. Finally, conditioned media were
filtered in 0.22-μm filters and concentrated 10 times (v/v)
using 3 kDa cutoff filters (Millipore, USA). To completely
eliminate DFX from the conditioned medium, the concen-
trates were washed twice with 15ml of PBS and re-
concentrated using the same filters.
Systemic administration of MSC-derived conditioned
medium
At 18 weeks of age, diabetic (db/db) mice were randomly
divided into three groups. The first group of mice was
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treated with intravenous administration of 50 μl of condi-
tioned medium derived from 1 × 106 DFX-preconditioned
AD-MSCs. The second group was treated with intraven-
ous administration of 50 μl of conditioned medium de-
rived from 1 × 106 non-preconditioned AD-MSCs, while
the third group received intravenous administration of
50 μl of vehicle. Conditioned medium or vehicle adminis-
tration was repeated every 2 weeks for a total of four ad-
ministrations. An additional group of normal non-diabetic
(db/+) mice treated with vehicle was used as a healthy
control (Supplementary Figure 1).
Measurement of blood glucose
Non-fasting blood glucose levels were measured using a
glucometer (Accu-Chek Performa System; Roche,
Switzerland). Blood samples were obtained from the tail
of alert animals every 2 weeks (from week 14 to week
26).
Determination of thermal sensitivity
At 14, 18, 22, and 26 weeks of age, mice were placed in
an acrylic box provided with an infrared light (Ugo
Basile Plantar Test, Italy) 20 min before measuring the
withdrawal latency. Then, the infrared light was placed
beneath the mid-plantar surface of hind paws, and the
withdrawal responses were automatically recorded. The
cutoff latency was set at 15 s to avoid hind paw damage.
The stimulation was repeated three times with an inter-
val of 5 min between stimuli, during two consecutive
days. Eight animals per experimental group were evalu-
ated. Data were expressed as the mean withdrawal la-
tency registered each day [33].
Determination of mechanical sensitivity
At 14, 18, 22, and 26 weeks of age, mice were placed in
an acrylic box with a mesh floor that allowed free access
to the plantar surface of the paw 20 min before evalu-
ation. Then, the mid-plantar surface of hind paws was
stimulated with an electronic Von Frey filament (Ugo
Basile Electronic Von Frey, Italy) with increasing force,
and the responses were automatically recorded. The
stimulation was repeated three times with an interval of
5 min between stimuli, during two consecutive days.
Eight animals per experimental group were evaluated.
Data were expressed as the mean withdrawal force regis-
tered each day [33].
Quantification of nerve conduction velocity
Motor nerve conduction was determined bilaterally in
the sciatic nerves. For this, animals were anesthetized by
sevoflurane vapors and placed on a hot plate to maintain
a constant temperature of 33 °C. For determination of
motor conduction velocity, the sciatic nerve was stimu-
lated by a supramaximal pulse of 50 μs duration with an
electromyograph (Medelec, UK) with surface electrodes
placed into the sciatic notch and ankle. The distance be-
tween the active and referential electrode was kept con-
stant at 6 mm. Signals were amplified with a bandpass 2
Hz-5KHz analog filter. Signals were analyzed by Medelec
software as previously described [33].
Quantification of intraepidermal nerve fiber density
At 26 weeks of age, mice were euthanized by a keta-
mine/xylazine overdose. The footpads were dissected
from the plantar surface of the hind paws and fixed in
4% paraformaldehyde (Merck, USA) for 15 min. The pad
samples were immersed in 20% sucrose for 72 h and em-
bedded in Tissue-Tek O.C.T. (Sakura Finetek, USA).
The pads were cryosectioned at 15 μm, blocked with 5%
fish gelatin, and stained against the axonal protein
PGP9.5 (1:150, ab1761 Millipore, USA) as previously re-
ported [33]. Nuclei were counterstained with DAPI
(Applichem, Spain). A stack of eight images per footpad
was obtained in a Fluoview FV10i confocal microscope
(Olympus, Japan). Samples from six animals per experi-
mental group were evaluated. Data were expressed as
number of fibers crossing from dermis to epidermis per
linear mm of skin [33].
Morphometric analysis of sciatic nerve
At 26 weeks of age, sciatic nerves were dissected and
fixed in 2.5% glutaraldehyde (Polisciences Inc., USA).
Then, samples were post-fixed in 1% osmium tetroxide
and embedded in epoxy resin (Sigma-Aldrich). For nerve
fiber analysis, semithin (0.5 μm) transverse sections were
stained with toluidine blue (Sigma-Aldrich), and the area
and density of individual fibers were quantified using
ImageJ software (NIH, USA). For ultrastructural analysis
of the fibers, ultrathin sections were stained with 5% ur-
anyl acetate and 3% lead citrate (Sigma-Aldrich) and ex-
amined with a Phillips Morgani electron microscope. G-
ratio was analyzed as previously described [34], evaluat-
ing small caliber fibers (< 6 μm diameter) separately from
large fibers (≥ 6 μm diameter). Mitochondrial area and
density were quantified from electron microscopy im-
ages from sciatic nerves, using ImageJ software. Samples
from six animals per experimental group were evaluated.
Primary cultures of dorsal root ganglia (DRG) and Sholl
analysis
DRGs from L3 and L4 were dissected from 26-week-old
animals and enzymatically digested by incubation for 25
min at 37 °C with 0.6% trypsin (Gibco) and then for 25
min at 37 °C with 0.5% collagenase type I (Gibco). The
enzymatic activity was halted by adding 1ml of fetal bo-
vine serum (FBS), and tissue suspension was centrifuged
at 400g for 5 min. Then, the pellet was resuspended in
DMEM/F12 (Gibco) with 10% FBS and mechanically
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dissociated. Five thousand cells were plated on coverslips
coated with 0.05% poly-D-lysine (Sigma-Aldrich). Neu-
rons were allowed to attach to the substratum for 4 h
before changing medium to DMEM/F12 containing N2
supplement (Gibco). After 40 h in culture, cells were
fixed with 4% paraformaldehyde containing 4% sucrose
during 20 min, neurons were immunostained with β3-
tubuline antibody (TU-20, Santa Cruz Biotechnology;
secondary antibody: anti mouse AlexaFluor-488, Cell
Signaling, USA), and nuclei were counterstained with
DAPI. Samples were analyzed by confocal microscopy.
Sholl analysis was carried out as previously described
[35]. Briefly, confocal images were transformed to 8-bit
binary images, and the estimated soma center was
marked. Images were analyzed with the Sholl analysis
tool using ImageJ software. The distance/neurite number
profile, the maximum radius reached by each neuron,
and the sum of intersections for each neuron was evalu-
ated. As positive control for neuritogenesis, samples
were incubated with 10 ng/ml NGF (Alamone Labs,
Israel). To avoid the quantification of neurite growth in
dying neurons, we only analyzed neurons extending at
least one neurite ≥ 20 μm. Samples from four animals
per experimental group were evaluated.
Determination of apoptosis in DRG and sciatic nerves
At 26 weeks of age, DRG (L3) and sciatic nerves were
extracted, fixed in 4% paraformaldehyde and embedded
in paraffin. Apoptotic cells were identified in 4-μm thick
sections using the DeadEnd™ Fluorometric TUNEL sys-
tem (Promega, USA). Nuclei were counterstained with
DAPI. TUNEL-positive nuclei were quantified using
ImageJ software. Samples from six animals per experi-
mental group were evaluated. Data were expressed as
the percentage of apoptotic cells [33].
Quantification of microvasculature and T cell and
macrophage infiltration in the sciatic nerve
At 26 weeks of age, sciatic nerves and gastrocnemius
muscle were removed and fixed in 4% paraformaldehyde
for 24 h. For microvasculature analysis, 10 μm longitu-
dinal cryosections of sciatic nerves were obtained. Sam-
ples were permeabilized with 1 mg/ml digitonin
(Calbiochem, USA) in phosphate buffer and incubated
with BS1-Lectin-Alexa-647 (1:100; Life Technologies,
USA) overnight. Nuclei were counterstained with DAPI.
The number of BS1-Lectin-Alexa-647-positive blood
vessels were quantified by confocal microscopy and nor-
malized related to nerve area. For determination of ca-
pillary to muscle fiber ratio, muscle samples were cut
into 5-μm sections and stained with hematoxylin and
eosin. The number of capillaries and muscle fibers were
counted in 10 fields from each section, and the capillary
to muscle fiber ratio was calculated. Samples from six
animals per experimental group were evaluated.
For T cell and macrophage infiltration analysis, 10-μm
longitudinal nerve cryosections were blocked for 1 h in
5% FBS, 0.025% Triton X-100, 0.5M TRIS buffer, and
stained against the CD3 antigen (1:100, Dako, Denmark)
or the CD11b antigen (1:100, eBioscience, USA), re-
spectively. Nuclei were counterstained with DAPI. The
number of CD3+ cells and CD11b+ cells were quantified
in a Fluoview FV10i confocal microscope and normal-
ized related to nerve area [33]. Samples from six animals
per experimental group were evaluated.
Quantification of mRNA levels of pro-inflammatory
factors in sciatic nerve
At 26 weeks of age, sciatic nerves were removed, and
total RNA was purified using Trizol reagent (Invitrogen,
USA). One microgram of total RNA was used to per-
form reverse transcription with MMLV reverse tran-
scriptase (Invitrogen) and oligo-dT primers. Real-time
PCR reactions were performed to amplify the pro-
inflammatory cytokines TNF-α and IL-1β using a Light-
Cycler 1.5 thermocycler (Roche, USA). Relative quantifi-
cations were performed by the ΔΔCT method [30]. The
mRNA level of each target gene was normalized against
the mRNA levels of β-actin in the same sample. Samples
from six animals per experimental group were evaluated.
Wound induction and ulcer area measurement
At 26 weeks of age (2 weeks after the last administration
of conditioned medium or vehicle), animals were anes-
thetized with sevoflurane vapors (Abbott, Japan), and a
layer of skin (2.5 × 3.5 mm) in full thickness was surgi-
cally removed from the dorsal surface of both feet.
Digital images were taken daily for 14 days, and the foot
ulcer area (mm2) was quantified using ImageJ software
as previously described [36]. Wound size for each day
was defined as the area that was not re-epithelized and
was normalized by the initial wound area. Six animals
per experimental group were evaluated.
Evaluation of wound re-epithelialization, angiogenesis,
and cell proliferation
Two weeks after wounding, animals were euthanized by
a ketamine/xylazine overdose. The wound area was ex-
cised, fixed in 4% paraformaldehyde, and then bisected
through the center of the lesion to obtain the largest
diameter of the wound. For determination of epidermal
area and collagen deposition, 5-μm sections were stained
with hematoxylin and eosin and Masson’s trichrome, re-
spectively. Epidermal area and collagen deposition were
quantified using ImageJ software as previously described
[37]. For blood vessel quantification, 5-μm sections were
permeabilized with 1 mg/ml digitonin and incubated
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with BS1-Lectin-Alexa-647 (1:100) overnight. Nuclei
were counterstained with DAPI. For VE-cadherin-based
vasculature analysis, 5-μm sections were blocked for 1 h
in 5% FBS, 0.025% Triton X-100, 0.5 M TRIS buffer, and
stained using the VE-cadherin antibody (1:100, sc-6458,
Santa Cruz Biotechnology). Nuclei were counterstained
with DAPI. The dermal area positive for BS1-Lectin or
VE-cadherin was quantified from Z-stack images (Fluo-
view FV10i confocal microscope) using ImageJ software
and expressed as a percent of total dermal area.
For assessment of cell proliferation inside the wound,
5-μm sections were blocked for 1 h with 5% FBS, 0.025%
Triton X-100, 0.5M TRIS buffer, and stained against the
nuclear antigen Ki67 (1:400, ab15580 Abcam, UK), and
nuclei were counterstained with DAPI. The number of
KI67+ cells was quantified in a Fluoview FV10i confocal
microscope and expressed as percentage of proliferating
cells in the wound. Samples from six animals per experi-
mental group were evaluated for each analysis.
Quantification of mRNA levels of angiogenic and matrix-
related factor in the wound
One week after wounding, animals were euthanized by a
ketamine/xylazine overdose. Wound area was excised,
and total RNA was purified using Trizol. One micro-
gram of total RNA was used to perform reverse tran-
scription with MMLV reverse transcriptase and oligo-dT
primers. Real-time PCR reactions were performed to
amplify the angiogenic factors Angiopoietin-1, PDGF,
IGF-1, and VEGF-α and the matrix-related factors colla-
gen 1 using a Light-Cycler 1.5 thermocycler as reported
above. Samples from six animals per experimental group
were used.
Proteomic analysis of AD-MSC-derived conditioned media
The protein composition of conditioned media derived
from DFX-preconditioned and non-preconditioned AD-
MSCs obtained from four donors were analyzed as follows.
Proteins were denatured and digested by trypsin as previ-
ously described [38]. Peptides were analyzed by nanoLC-
MS/MS on a Q-Exactive “classic” mass spectrometer
(Thermo Fisher Scientific, USA) in data-dependent mode.
Three technical replicates were acquired for each biological
replicate under consideration, in order to improve the ac-
curacy of protein quantification. Data were processed in the
MaxQuant/Perseus software suite (v.1.6.2) for protein iden-
tification and label-free quantification [39]. Differentially
abundant proteins were assigned by performing two-sided
Student’s t tests with S0 = 0.2 as the correction factor and
permutation-based estimate of FDR (FDR < 0.05). Func-
tional enrichment analysis of differentially abundant pro-
teins was performed using Reactome [40], Gene Ontology
(Molecular Function and Biological Process) [41], KEGG
[42], and Wiki Pathways [43] databases through enrichR
web server [44]. A functional category was considered
enriched if presented an adjusted p value smaller than 0.05.
The interaction network analysis of selected proteins was
performed using Genemania web server [45], considering
interactions related to “co-expression,” “co-localization,”
“physical interactions,” “pathway,” “predicted,” and “genetic
interactions” as defined by the tool.
Statistical analysis
Quantitative data were presented as mean ± S.E.M.
Comparisons between groups were performed using
one-way ANOVA with Tukey post-test. Grouped, re-
peated measures were analyzed with two-way ANOVA
with Bonferroni post-test. p values < 0.05 were consid-
ered statistically significant.
Results
AD-MSC-conditioned medium administration improves
thermal and mechanical sensitivity and restores
intraepidermal nerve fiber density
To evaluate the therapeutic potential of AD-MSC-
derived conditioned medium, we administered systemic-
ally 50 μl of conditioned medium derived from 1 × 106
DFX-preconditioned AD-MSCs or from 1 × 106 non-
preconditioned AD-MSCs into diabetic db/db mice at
18 weeks of age, when functional alterations characteris-
tic of DPN were already present (Fig. 1a, b) [33]. Condi-
tioned medium or vehicle administration was repeated
every 2 weeks (due to the ability of its protein compo-
nents), for a total of four administrations (Supplemen-
tary Figure 1).
The effect of conditioned medium administration on
sensorial parameters of DPN was determined evaluat-
ing thermal and mechanical nociceptive thresholds
using the plantar test and Von Frey test, respectively.
We observed that administration of conditioned
medium derived from DFX-preconditioned AD-MSCs
or from non-preconditioned AD-MSCs to diabetic
mice significantly reduced thermal hypoalgesia (Fig. 1a)
and fully recovered mechanical sensitivity (Fig. 1b)
compared to vehicle-treated diabetic animals.
Intraepidermal nerve fibers (IENF) are directly associ-
ated with functional innervation of the skin, and its re-
duction constitutes one of the main DPN histological
features in humans, since it is associated with small fiber
neuropathy [46]. To evaluate IENF density, we carried
out an immunodetection of the PGP 9.5 antigen in cryo-
sections of the hind limb plantar skin at 26 weeks of age,
and we quantified the number of fibers crossing from
the dermis to the epidermis per millimeter of linear skin.
As expected, we observed that vehicle-treated diabetic
animals had a significant reduction of IENF density
compared to non-diabetic mice; however, the condi-
tioned medium administration partially reversed IENF
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loss (Fig. 1c, d). Conditioned medium administration
had no effect on blood glucose levels or body weight
gain (Supplementary Figure 2A and B), suggesting that
sensory improvement is a direct effect of conditioned
medium administration.
Another physiological feature of DPN is the reduction
of nerve conduction velocity in peripheral nerves [47].
To study the electrophysiological changes in peripheral
nerves, we measured the compound motor action
potential (CMAP) by stimulating the sciatic nerves of
diabetic and healthy mice. Electrophysiological record-
ings derived from vehicle-treated diabetic mice showed
decreased CMAP amplitude and increased mean peak
latency (Supplementary Figure 3A-B) compared with
non-diabetic mice. Conditioned medium administration
induced a slightly increase in CMAP amplitude; how-
ever, we did not observe significant differences in mean
peak latency (Supplementary Figure 3A-B).
Fig. 1 AD-MSC-conditioned medium administration improves thermal and mechanical sensitivity and restores intraepidermal nerve fiber density
in diabetic mice. a, b Hargreaves plantar test (a) and Von Frey test (b) showing the withdrawal latency to thermal stimulus and withdrawal
threshold to mechanical stimulus, respectively, in non-diabetic and diabetic mice treated with vehicle, conditioned medium derived from non-
preconditioned AD-MSCs, or conditioned medium derived from DFX-preconditioned AD-MSCs. c Representative confocal images of
intraepidermal nerve fibers from plantar skin samples obtained from 26-week-old non-diabetic and diabetic mice treated with vehicle,
conditioned medium derived from non-preconditioned AD-MSCs, or conditioned medium derived from DFX-preconditioned AD-MSCs stained
against the PGP 9.5 antigen. Asterisks indicate intraepidermal nerve fibers. d Quantification of the number of fibers crossing from dermis to
epidermis per mm of linear skin. Data are presented as mean ± S.E.M. (n = 8, two-way ANOVA with Bonferroni post-test, *p < 0.05)
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AD-MSC-conditioned medium administration recovers
sciatic nerve ultrastructure
Previous reports have indicated that both in humans and
in animal models, DPN alters the morphology of nerve
fibers [47]. To explore these morphological alterations,
we obtained semithin sections of sciatic nerve and evalu-
ated the size distribution of nerve fibers. As previously
reported, we detected a significant decrease in the fre-
quency of large fibers (> 12 μm diameter) in the sciatic
nerve of vehicle-treated diabetic mice compared to non-
diabetic mice (Fig. 2a, b). However, the administration of
conditioned medium derived from DFX-preconditioned
AD-MSCs or non-preconditioned AD-MSCs completely
reversed the degeneration of large nerve fibers (Fig. 2a,
b). At ultrastructural level, we observed that fibers from
diabetic mice present some structural defects that were
absent or less frequent in non-diabetic animals, includ-
ing the disruption of the compacted structure of myelin
sheets and the separation of shrunken axon from myelin
sheath (Fig. 2c), as previously described in other animal
models of DPN [21, 48–50]. These defects have been
considered as early steps of neurodegeneration; mean-
while, we did not detect evident signs of axonal degener-
ation, such as mitochondria swelling, Schwann cell
vacuolation and collapse, and myelin breakdown (Sup-
plementary Figure 4) [51].
Fig. 2 AD-MSC-conditioned medium administration recovers sciatic nerve ultrastructure in diabetic mice. a Representative bright-field images of
semithin sections of sciatic nerves obtained from 26-week-old non-diabetic and diabetic mice treated with vehicle, conditioned medium derived
from non-preconditioned AD-MSCs, or conditioned medium derived from DFX-preconditioned AD-MSCs. Myelinated fibers were stained with
toluidine blue. b Frequency distribution histogram of myelinated fibers. c Representative electron microscopy images of ultrathin sections of
sciatic nerves. Asterisks indicate fibers with disrupted myelin sheath, and arrows indicate the separation of shrunken axon from myelin sheath. d
G-ratio quantification for small caliber (< 6 μm diameter) and large caliber (> 6 μm diameter) myelinated fibers of sciatic nerve. Qualitative data are
presented as mean ± S.E.M. (n = 6, one way ANOVA with Tukey post-test, *p < 0.05)
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Though DM is not considered a demyelinating disease,
it has been described that fibers form peripheral nerves
suffer a progressive myelin loss in human patients and
in animal models of DPN [52, 53]. To evaluate nerve
fiber demyelination, we quantified the G-ratio (ratio
axon diameter/nerve fiber diameter) in myelinated fibers
of sciatic nerves. We observed that demyelination was
more evident in small fibers, while large fibers did not
seem affected. Thus, we analyzed G-ratio in small fibers
(< 6 μm diameter) and large fibers (> 6 μm diameter)
separately, as previously reported [53, 54]. Our results
showed that G-ratio was increased specifically in small
caliber fibers of diabetic animals compared to non-
diabetic mice, and this demyelination was completely re-
versed by the administration of conditioned medium de-
rived from preconditioned and non-preconditioned AD-
MSCs (Fig. 2d). Large caliber fibers presented similar G-
ratio in all experimental groups, indicating that severe
myelin alterations could be observed mainly in advanced
stages of the disease, as previously reported for other
animal models of T2DM [34].
AD-MSC-conditioned medium administration increases
neurite regeneration in DRG neuronal cultures
Clinical and experimental evidence indicates that axonal
regeneration is highly impaired in DPN [55, 56]. To as-
sess the contribution of in vivo AD-MSC-conditioned
medium treatment to the regenerative response in sen-
sorial neurons, we obtained DRG from conditioned
medium and vehicle-treated diabetic mice and we cul-
tured the disaggregated DRG neurons in vitro as a sim-
plified system for studying axonal regeneration [57].
After 40 h in culture in the absence of growth factors
and fetal bovine serum, DRG neurons were fixed and
stained with the neuronal specific marker β3-tubulin for
evaluation of neurite regeneration by Sholl analysis. We
observed that DRG neurons obtained from vehicle-
treated diabetic mice displayed reduced neurite length
and branching compared to DRG neurons obtained from
non-diabetic mice, as assessed by Sholl maximum radius
and mean Sholl intersections per neuron, respectively
(Fig. 3a–d). Interestingly, conditioned medium derived
from DFX preconditioned AD-MSCs and from non-
preconditioned AD-MSCs completely reversed the im-
paired regeneration phenotype associated to the diabetic
condition (Fig. 3a–d).
AD-MSC-conditioned medium administration reduces
apoptosis in DRG and sciatic nerves
It has been reported that due to the high mitochondrial
density in neurons and Schwann cells, these cells are
early affected by the oxidative microenvironment in the
diabetic condition, resulting in an increased apoptotic
rate [58]. To evaluate this parameter, we performed a
TUNEL assay in DRGs and sciatic nerves obtained from
diabetic and non-diabetic mice and quantified the num-
ber of TUNEL+ cells. As expected, we observed that
vehicle-treated diabetic mice had a significant increase
in the number of apoptotic cells at DRG and sciatic
nerve levels compared to age-matched non-diabetic mice
(Fig. 4a–d). Conditioned medium administration signifi-
cantly reduced the number of apoptotic cells in DRG
and sciatic nerve (Fig. 4a–d).
AD-MSC-conditioned medium administration improves
irrigation of peripheral nerves
The reduction of microvasculature of peripheral nerves
is a classical hallmark of DPN in human patients [59].
Thus, we measured blood vessels in longitudinal cryo-
sections of sciatic nerve stained with BS-1-Lectin to label
endothelial cells. Additionally, the vasculature in the
gastrocnemius muscle surrounding the nerve was evalu-
ated by hematoxylin and eosin staining, and the blood
vessel-to-muscle fiber ratio was determined. As ex-
pected, we observed that vehicle-treated diabetic mice
had a significant reduction in blood vessel in the sciatic
nerve (Fig. 5a, b) and muscle (Fig. 5c, d) compared to
non-diabetic mice. However, conditioned medium ad-
ministration recovered blood vessel density in both
structures (Fig. 5a–d). The administration of conditioned
medium derived from DFX-preconditioned AD-MSCs
had a more potent effect recovering the sciatic nerve
vasculature compared to non-preconditioned AD-MSC-
conditioned medium-treated animals (Fig. 5a, b).
AD-MSC-conditioned medium administration reduces
sciatic nerve chronic inflammation
The generation of chronic inflammation in peripheral
nerves directly contributes to nerve degeneration and
chronic pain [60]. To evaluate T lymphocyte and macro-
phage infiltration in peripheral nerves, we performed an
immunofluorescence analysis against the CD3 and CD11b
antigens in sciatic nerves. A significant increase in T
lymphocyte and macrophage infiltration was observed in
sciatic nerves of vehicle-treated diabetic mice compared to
non-diabetic mice, while the administration of condi-
tioned medium derived from DFX-preconditioned AD-
MSCs or non-preconditioned AD-MSCs restored T
lymphocyte and macrophage infiltration to normal levels
(Fig. 6a–d).
Following this process and in order to evaluate the pos-
sible immunomodulatory action of conditioned medium in
sciatic nerves, we evaluated the production of the main
pro-inflammatory cytokines by RT-qPCR. Our analysis
demonstrated that vehicle-treated diabetic mice exhibited
an upregulation of IL-1β and TNF-α mRNA levels relative
to non-diabetic mice (Fig. 6e). However, pro-inflammatory
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cytokines levels were restored to normal level after condi-
tioned medium administration (Fig. 6e).
AD-MSC-conditioned medium administration accelerates
wound healing
The main complication associated to DPN is the recur-
rent formation of FU. To evaluate whether conditioned
medium administration, in addition to reverse several
hallmarks of DPN, is able to prevent the formation of
FU, we wounded the dorsal surface of the hind limbs
2 weeks after the last conditioned medium administra-
tion and measured the wound area daily. We observed a
significant delay in wound closure in vehicle-treated dia-
betic mice compared to non-diabetic mice (Fig. 7a, b).
However, the previous treatment with conditioned
medium derived from DFX-preconditioned AD-MSCs or
non-preconditioned AD-MSCs significantly accelerated
wound healing (Fig. 7a, b). Histological analysis of the
wound bed was performed to further evaluate the heal-
ing of the foot skin ulcers. Fourteen days after wound in-
duction, we measured the epidermal area and collagen
deposition in the wound by hematoxylin and eosin stain-
ing and by Masson’s trichrome staining, respectively.
Vehicle-treated diabetic mice presented a significant in-
crease in wound epidermal area (Fig. 7c, e) and a signifi-
cant reduction in collagen deposition in the wound bed
(Fig. 7d, f). These results were correlated with a signifi-
cant reduction in the expression level of type I collagen
Fig. 3 AD-MSC-conditioned medium administration increases neurite regeneration in DRG neuronal cultures derived from diabetic mice. a
Representative binary images of DRG neurons cultured in vitro derived of non-diabetic and diabetic mice treated in vivo with vehicle,
conditioned medium derived from non-preconditioned AD-MSCs, or conditioned medium derived from DFX-preconditioned AD-MSCs. b Sholl
analysis of neurons. c Quantification of maximum radius and d number of intersections per neuron derived from Sholl analysis (n = 4 different
cultures, 120 total neurons analyzed per condition, one-way ANOVA with Tukey post-test, *p < 0.05)
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evaluated 7 days after wound induction (Fig. 7g), sug-
gesting the presence of an altered re-epithelialization
process in these animals. Conditioned medium adminis-
tration completely normalized epidermal area and colla-
gen deposition in diabetic mice (Fig. 7c–f) and restored
the normal expression levels of type I collagen in the
wounds (Fig. 7g).
AD-MSC-conditioned medium administration improves
the angiogenesis of the wounds
One of the main complications of diabetic wound healing
is the reduced angiogenesis present in the injured skin.
Thus, to better characterize the re-epithelialization
process, we evaluated the vascular network in the wound
by BS-1-Lectin staining, which binds to glycoproteins
present in endothelial cells, and by VE-cadherin staining
to specifically label endothelial cells, 14 days after wound
induction. As expected, vehicle-treated diabetic mice pre-
sented a significant reduction of the wound vascular area
measured by both markers compared to non-diabetic
mice (Fig. 8a–d), which was correlated with a significant
reduction in the expression level of several potent angio-
genic factors evaluated by RT-qPCR 7 days after wound
induction (Fig. 8e). In contrast, animals treated with con-
ditioned medium derived from DFX-preconditioned AD-
MSCs or non-preconditioned AD-MSCs had a significant
improvement in the vascular area of the wound (Fig. 8a–
d), and the expression levels of several angiogenic factors
were similar to age-matched healthy mice (Fig. 8e). Once
again, the administration of conditioned medium derived
from DFX-preconditioned AD-MSCs had a more potent
effect in recovering the skin vasculature compared to non-
preconditioned AD-MSC-conditioned medium-treated
mice (Fig. 8a–d).
Fig. 4 AD-MSC-conditioned medium administration reduces neuronal and Schwann cell apoptosis in DRGs and sciatic nerves of diabetic mice. a,
b Representative confocal images of apoptotic cells labeled with the TUNEL staining in DRGs (a) and sciatic nerves (b), obtained from 26-week-
old non-diabetic and diabetic mice treated with vehicle, conditioned medium derived from non-preconditioned AD-MSCs, or conditioned
medium derived from DFX-preconditioned AD-MSCs. Nuclei were counterstained with DAPI. Arrows indicate TUNEL+ cells. c, d Quantification of
TUNEL+ cells in c DRGs and d sciatic nerves. Data are presented as mean TUNEL+ cells ± S.E.M. (n = 6, one-way ANOVA with Tukey
post-test, *p < 0.05)
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Given that cellular proliferation in the wound tissue
may contribute to ulcer healing, we next evaluated
whether conditioned medium administration promoted
cellular proliferation by analyzing Ki67 immunostaining.
As expected, we observed that, 14 days after wound in-
duction, vehicle-treated diabetic animals had a signifi-
cant reduction in Ki-67+ cells in the wound bed
compared to non-diabetic mice (Fig. 8f, g). Conditioned
medium administration partially reversed the reduction
in cell proliferation in the wound (Fig. 8f, g).
Proteomic analysis of conditioned medium derived from
non-preconditioned AD-MSCs and from DFX-
preconditioned AD-MSCs
Finally, we performed a nLC-MS/MS analysis to identify
differentially secreted proteins between non-preconditioned
AD-MSCs and DFX-preconditioned AD-MSCs. Four con-
ditioned media of each experimental condition were ana-
lyzed, and a total of 569 proteins were identified in both
conditions. The majority of these proteins did not present
differences when comparing DFX-preconditioned and non-
Fig. 5 AD-MSC-conditioned medium administration improves irrigation of peripheral nerves in diabetic mice. a Representative confocal images of
longitudinal sections of sciatic nerves obtained from 26-week-old non-diabetic and diabetic mice treated with vehicle, conditioned medium
derived from non-preconditioned AD-MSCs, or conditioned medium derived from DFX-preconditioned AD-MSCs. Blood vessels were stained with
BS-1Lectin. b Quantification of vascular area in sciatic nerves. c Representative bright-field images of gastrocnemius muscle sections stained with
hematoxylin and eosin for blood vessel detection. Arrows indicate blood vessels. d Quantification of blood vessel density in gastrocnemius
muscle. Data are presented as number of blood vessels per muscle fiber. Quantitative data are presented as mean ± S.E.M. (n = 6, one-way ANOVA
with Tukey post-test, *p < 0.05)
Gregorio et al. Stem Cell Research & Therapy          (2020) 11:168 Page 12 of 21
preconditioned AD-MSCs conditions (Fig. 9a, b), indicating
that both conditioned media are similar in most of its
protein components. However, slight differences were
attributed to 17 proteins that were found overex-
pressed and 11 proteins that were downregulated in
the DFX-preconditioned AD-MSCs condition com-
pared to the non-preconditioned condition (Fig. 9b,
c). In order to recover additional information related
to the functional roles that these differentially abun-
dant proteins could be involved in, we performed an
overrepresentation enrichment analysis using different
databases related to function, pathways, and biological
processes. The overrepresentation analysis revealed a
significant enrichment in proteins associated with
angiogenesis, response to hypoxia, extracellular matrix
organization, and endothelial cell migration (Fig. 9d),
which are highly related to the improved vasculogenic
effect of the conditioned medium derived from DFX-
preconditioned AD-MSCs in sciatic nerves and skin
wounds. Additionally, network analysis revealed a
high connectivity within some hub proteins presenting
functional associations with “angiogenesis,” “sprouting
angiogenesis,” “endothelial cell proliferation,” “blood
vessels morphogenesis,” and “response to hypoxia”
Fig. 6 AD-MSC-conditioned medium administration reduces sciatic nerve inflammation in diabetic mice. a, b Representative confocal images of
longitudinal sections of sciatic nerves obtained from 26-week-old non-diabetic and diabetic mice treated with vehicle, conditioned medium
derived from non-preconditioned AD-MSCs, or conditioned medium derived from DFX-preconditioned AD-MSCs. T lymphocytes were detected
with anti-CD3 antibody (a) while macrophages were detected with anti-CD11b antibody (b). Nuclei were stained with DAPI. Arrows indicates
CD3+ cells or CD11b+ cells. c Quantification of CD3+ cells in sciatic nerve. Data are presented as number of CD3+ cells per 0.5 mm2 of sciatic
nerve. d Quantification of CD11b+ cells in sciatic nerve. Data are presented as number of CD11b+ cells per 0.5 mm2 of sciatic nerve. e
Quantification of mRNA levels of the pro-inflammatory cytokines IL-1β and TNF-α in the sciatic nerve. Data were normalized against the
housekeeping gene β-actin. Quantitative data are presented as mean ± S.E.M. (n = 6, one-way ANOVA with Tukey post-test, *p < 0.05)
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(Fig. 9e). However, more research is needed to iden-
tify which are the more relevant molecules behind the
observed therapeutic effects.
Discussion
Diabetic polyneuropathy is a clinical complication of
DM that evolves from functional peripheral nerve im-
pairments in the early phases of the disease toward
structural changes at advanced stages [61]. Using one of
the most relevant animal models of T2DM [31–33], the
present study demonstrated that the systemic adminis-
tration of conditioned medium derived from DFX-
preconditioned AD-MSCs or from non-preconditioned
AD-MSCs effectively blocked the main functional and
structural features associated with DPN by modulating
different pathways, once the main alterations associated
to DPN were already established. Furthermore, DPN re-
version induced by conditioned medium administration
enhanced the wound healing process, which could be
useful as a preventive treatment for FU formation in dia-
betic patients.
The pathogenesis of DPN is multifactorial, involving
both metabolic and vascular components. However, at
molecular level, the increase in ROS level in mitochon-
dria due to exacerbated glucose flux has been proposed
as the central player in DPN onset and progression [7].
Increased ROS levels lead to a severe deficiency of an-
giogenic and neuroprotective factors and to an increase
in pro-inflammatory factors, which finally result in the
generation of nerve structural damage at several levels
[7]. Thus, a therapeutic approach simultaneously target-
ing the angiogenic, neurodegenerative, inflammatory,
and oxidative process may have great value in DPN
treatment.
In recent years, MSCs have emerged as a tool with
great clinical potential in the treatment of multifactorial
diseases. These cells can be isolated from a wide range
of tissue [62]. Nevertheless, adipose tissue has been
Fig. 7 AD-MSC-conditioned medium administration accelerates wound healing in diabetic mice. a Representative digital photographs of the
dorsal surface of the feet of 26-week-old non-diabetic and diabetic mice treated with vehicle, conditioned medium derived from non-
preconditioned AD-MSCs, or conditioned medium derived from DFX-preconditioned AD-MSCs at different days after wound induction. b
Quantification of kinetics of wound closure. Wound size for each day was defined as the area that was not re-epithelized and was normalized by
the initial wound area. c Representative bright-field images of hematoxylin and eosin-stained histological sections of the wounds, 14 days after
wound induction, for evaluation of epidermal area. d Representative bright-field images of Masson’s trichrome stained histological sections of the
wounds, 14 days after wound induction for evaluation of collagen deposition. e Quantification of epidermal area in the wound bed. f
Quantification of collagen deposition in the wound bed. g Quantification of mRNA levels of type I collagen in the wound bed 7 days after
wound induction. Data were normalized against the housekeeping gene β-actin. Quantitative data are presented as mean ± S.E.M. (n = 6, one-way
ANOVA with Tukey post-test, *p < 0.05)
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positioned as the preferred source for MSC isolation due
to is accessibility, since it is considered a waste material
of cosmetic liposuctions and has a higher yield of MSCs
compared to other sources [63].
MSC therapy has shown promising results in the treat-
ment of DPN at pre-clinical level [18, 20, 21]. However,
limited cell survival after transplantation, due to the
noxious microenvironment, the non-specific organ en-
trapment, the possible differentiation of MSCs into ec-
topic structures, the elimination of the cells by the host
immune system, and possible tumorigenicity hinders its
transfer from bench to bedside [64].
Fig. 8 AD-MSC-conditioned medium administration improves the angiogenesis of the wounds in diabetic mice. a, b Representative confocal
images of histological sections of the wound obtained from 26-week-old non-diabetic and diabetic mice treated with vehicle, conditioned
medium derived from non-preconditioned AD-MSCs, or conditioned medium derived from DFX-preconditioned AD-MSCs, 14 days after wound
induction. Blood vessels were stained with BS-1Lectin (a) or VE-cadherin (b) and nuclei were stained with DAPI. c, d Quantification of the vascular
area in the wound 14 days after wound induction for BS1-Lectin labeling (c) or VE-cadherin labeling (d). e Quantification of mRNA levels of pro-
angiogenic factors IGF-1, angiopotetin-1, PDGF, and VEGF-α in the wound bed, 7 days after wound induction. Data were normalized against the
housekeeping gene β-actin. f Representative confocal images of histological sections of the wound, 14 days after wound induction. Proliferating
cells in the wound were detected with anti-Ki67 antibody. Nuclei were stained with DAPI. Arrows indicates Ki67 positive cells. g Quantification of
proliferating cells in the wound 14 days after wound induction. Data are presented as percentage of Ki67 cells per square millimeter of wound
area. Quantitative data are presented as mean ± S.E.M. (n = 6, one-way ANOVA with Tukey post-test, *p < 0.05)
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The broad spectrum of molecules secreted by MSCs is
known as conditioned medium. In humans, the MSC-
conditioned medium consists of hundreds of biologically
active molecules including anti-inflammatory cytokines,
trophic factors, and antioxidant molecules [65]. In fact,
the remarkable therapeutic potential of MSC-derived con-
ditioned medium has been consistently demonstrated in
several experimental models, including nervous system
disorders and a number of painful physical conditions
[66–69]. Thus, it has been proposed that conditioned
medium administration could mimic the therapeutic ef-
fects observed after the administration of MSCs, while at
the same time reducing the therapeutic complexity and
the potential unwanted effects associated with the admin-
istration of living cells [66–69]. However, a major issue as-
sociated with the use of MSC-conditioned medium is that
in several cases, the concentration of relevant molecules is
too low for therapeutic applications.
It has been reported that, due to the high plasticity of
MSCs, it is possible to modify the MSC-conditioned
medium baseline composition by subjecting these cells
to an in vitro preconditioning stimulus, thus producing
a biological product with a defined combination and ra-
tio of biomolecules specific for a determined pathology
[28, 70]. In this context, we recently reported that the
preconditioning of AD-MSCs with the hypoxic mimetic
agent deferoxamine increased the level of the hypoxia-
inducible factor HIF1α, which activates several intracel-
lular pathways that finally result in a significant increase
in the secretion of several potent angiogenic, neuropro-
tective, anti-inflammatory, and antioxidant factors [30],
which could enable the concerted effect necessary for
neurovascular recovery in DPN.
Our data indicate that systemic administrations of
conditioned medium derived from DFX-preconditioned
MSCs and form non-preconditioned MSCs were able to
Fig. 9 Mass spectrometry, functional enrichment, and network analysis of conditioned medium derived from non-preconditioned AD-MSCs and
from DFX-preconditioned AD-MSCs. a Heatmap representation comparing the LFQ intensity (log10) of all 569 proteins recovered from
conditioned medium derived from non-preconditioned AD-MSCs and from DFX-preconditioned AD-MSCs. b Volcano plot showing differentially
expressed proteins between conditioned media derived from both conditions. The (f) associated to VEGF-α protein indicates a 111 amino acids
(H0YBI8, UniProt) fragment different to the full length VEGF-α. c Histogram representing the set of 17 significantly overexpressed proteins in the
conditioned medium derived from DFX-preconditioned AD-MSCs compared to the conditioned medium derived from non-preconditioned AD-
MSCs. d Functional enrichment analysis (p value < 0.05) of the differentially expressed proteins according to Reactome, Gene Ontology (Molecular
Function and Biological Process), KEGG, and Wiki Pathways databases. Enriched functional categories were selected based on their association
with the angiogenesis process. e Network analysis of the selected overexpressed proteins according to different interaction categories and
protein functions based on Genemania web server. The proteomic analysis was carried out using 4 different biological samples per condition
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significantly relieve thermal and mechanical hypoalgesia
in diabetic mice, restoring the normal sensitivity thresh-
old compared to that of untreated diabetic mice. To cor-
relate the improvement in behavior sensory neuropathy
with a reduction in sensory small nerve fiber damage, we
analyzed intraepidermal nerve fiber density at the foot-
pads. Cutaneous sensory neurons include unmyelinated
C-fiber and myelinated Aδ-fibers and Aβ-fibers [71],
while thermal and mechanical sensitivity are determined
mainly by C-type small fibers and myelinated Aδ-fibers
[71]; all these fibers could be labeled using the PGP 9.5
antigen. We observed that the administration of both
conditioned medium were able to ameliorate the loss of
PGP-9.5+ nerve fibers. Interestingly, in human patients,
a strong correlation between sensory loss and reduced
PGP 9.5+ intraepidermal nerve fiber density has been de-
scribed, and intraepidermal nerve fiber density is nega-
tively correlated with diabetes duration [72]. Further
immunofluorescence analysis with markers for specific
fibers would be important in order to assess which fibers
are lost and recovered after conditioned medium
administration.
As previously reported in human patients [73] and in
animal models [47, 74], diabetic mice displayed a signifi-
cant decrease in large diameter nerve fibers (> 12 μm
diameter) in the sciatic nerve, which are characterized
by a lower electrical threshold and a higher conduction
velocity. Thus, the reduction in CMAP amplitude and
prolonged motor latencies observed in untreated dia-
betic mice could be related to the drop out of large mye-
linated axons and therefore a reduction in the number
of motor units responsible for the smaller size of the
CMAP. The administration of conditioned medium de-
rived from DFX-preconditioned AD-MSCs and from
non-preconditioned AD-MSCs completely prevented the
loss of large fibers, prevented common ultra-structural
alterations, and restored the normal G-ratio in small
diameter fibers of the sciatic nerve. However, it had a
partial effect in restoring the normal electrophysiological
properties, suggesting that additional factors may also
contribute to the nerve conduction alterations in dia-
betic mice. It has been reported that another mechanism
involved in saltatory propagation in myelinated nerve fi-
bers is the resting membrane potential that becomes
hyperpolarized as the result of an inhibition of inter-
nodal inward rectification induced by hyperglycemia
[75]. Thus, even though axonal diameter improves in
diabetic mice treated with conditioned medium adminis-
trations, this mechanism may explain the lack of con-
duction velocity improvement in these animals.
Neurons and Schwann cells are especially sensitive to
the damage induced by ROS, which leads to cell apop-
tosis [58]. By secreting a broad range of neuroprotective
factors, Schwann cells play a central role in neuron
survival but also in axonal regeneration of peripheral nerves
after injury [76]. Therefore, the early death of these cells in
DPN induces a significant reduction of the local levels of
neuroprotective factors, generating a vicious cycle that en-
hances nerve fiber degeneration and prevents their regener-
ation [77]. Using DRG neurons in culture as a simplified
system for studying axonal regeneration [57], we observed
that conditioned medium administration completely re-
versed the impaired regeneration phenotype associated with
the diabetic condition compared to neurons obtained
from vehicle-treated diabetic mice. Furthermore, the
administration of conditioned medium derived from DFX-
preconditioned AD-MSCs or from non-preconditioned
AD-MSCs significantly reduced the apoptosis of neurons
and Schwann cells in vivo. These effects could be related to
the presence of several neurotrophic and antiapoptotic fac-
tors including BDNF, NGF, and NT3 in the conditioned
medium [30].
Increased ROS levels induce alterations in endothelial
cells, generating loss of the vasodilatation capacity of
epineural blood vessels and reduction of angiogenic fac-
tors production. This phenomenon leads to a reduction
in the microcapillaries that irrigate nerve fibers, with the
induction of local ischemia and neuronal dysfunction
[59]. Thus, impairment of peripheral blood flow is one
of the major factors triggering DPN [59]. In our model,
DPN induced a significant reduction in blood vessel
density in sciatic nerves and a marked reduction in the
capillary-to-muscle fiber ratio compared to that of
healthy animals. However, conditioned medium admin-
istration fully restored the normal microvasculature,
which could be related to the presence of potent angiogenic
factors in the conditioned medium, since the administration
of conditioned medium derived from DFX-preconditioned
AD-MSCs, which is significantly enriched in angiogenic
factors [30], induced a better angiogenic response com-
pared to non-preconditioned AD-MSC-conditioned
medium-treated animals.
Accumulating evidence also suggests the involvement
of inflammatory process in the pathogenesis of DPN
[60, 78]. Increased oxidative stress leads to activation
of the poly ADP-ribose polymerase (PARP) pathway,
which is responsible for regulating pro-inflammatory
cytokine expression [60]. This creates a chronic in-
flammatory state that exerts direct toxic effects on
neurons and Schwann cells, accelerating the atrophy
of nerve fibers and contributing to the chronic pain
characteristic of DPN patients [60]. We observed that
vehicle-treated diabetic mice had a significant increase
in T lymphocyte and macrophage infiltration that was
correlated with a significant increase in the expression
levels of the pro-inflammatory cytokines TNF-α and
IL1β, which have been associated with chronic pain
[79]. However, after the administration of conditioned
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medium derived from DFX-preconditioned AD-MSCs or
from non-preconditioned AD-MSCs, neuroinflammation
was significantly blunted, with T lymphocyte and macro-
phage infiltration and pro-inflammatory cytokine produc-
tion restored to normal levels. These results are in
accordance with previous studies in diabetic animals indi-
cating that MSCs administration alters the inflammatory
response by shifting the cytokine profile to an anti-
inflammatory phenotype [80, 81].
Successful wound healing is a dynamic and complex
process including a series of coordinated events such as
inflammation, cell migration, proliferation, differenti-
ation, angiogenesis, and re-epithelialization [82]. How-
ever, several of these processes are severely affected in
diabetic patients [83]. Thus, chronic lower extremity
wounds have become the most common and severe
complication of DM.
Our data indicates that the previous administration of
conditioned medium derived from DFX-preconditioned
AD-MSCs and from non-preconditioned AD-MSCs
significantly accelerates the ulcer healing on the foot of
diabetic mice. This result was accompanied with the res-
toration of the normal epithelial thickness after wound
closure and the improvement in collagen expression
level and collagen deposition in the wound bed of condi-
tioned medium-treated diabetic mice compared to
vehicle-treated diabetic mice.
The paramount importance of blood supply in the
healing of wounds has long been appreciated, since it is
necessary to sustain and enhance newly formed granula-
tion tissue, which is essential to wound healing [83].
Diabetic animals presented a significant reduction in ca-
pillary density in the wound bed and a significant reduc-
tion in the expression levels of angiogenic factors.
However, these alterations were fully reversed in diabetic
mice treated with conditioned medium derived from
DFX-preconditioned AD-MSCs.
Keratinocyte and fibroblast proliferation and migration
into the wound is also an important factor in the re-
epithelialization process [84]. We observed that the dia-
betic microenvironment significantly reduced cell prolif-
eration in the wound. However, this effect was partially
reversed in conditioned medium-treated diabetic mice.
Additional research is needed in order to know the con-
tribution of conditioned medium administration in other
process affected during wound healing that could be
contributing to the improvement in wound closure ob-
served in conditioned medium treated diabetic mice.
There are some reports showing that the administra-
tion of MSCs or MSCs-derived conditioned medium dir-
ectly onto the wounds of diabetic animals improved
wound closure by promoting skin re-epithelialization
and improving the angiogenic process [85–87]. However,
since FU constantly occur in diabetic patients, this
complex procedure needs to be repeated whenever the
patient has a new ulcer. Here, we propose a different
therapeutic approach in which the systemic administra-
tion of conditioned medium at initial stages of DPN
could reverse functional and structural alterations of
peripheral nerves, avoiding the generation of FU, but
also accelerating the closure of the wound in case it
occurs.
In our study, no significant changes in blood glucose
levels was observed after conditioned medium adminis-
tration, suggesting that the conditioned medium-
mediated relief of functional and structural alterations
characteristic of DPN and the improvement in wound
healing are independent of glycemia.
Recently, we reported that conditioned medium ob-
tained from DFX-preconditioned AD-MSCs showed
greater neuroprotective effects compared with the condi-
tioned medium obtained from non-preconditioned AD-
MSCs, when evaluated in an in vitro model of DPN [30].
Here, our data showed that when conditioned media
were evaluated in an animal model of DPN, both were
equally potent in reversing the main functional and
structural alterations characteristic of DPN.
The main therapeutic differences between both condi-
tioned media were associated to the improvement of the ir-
rigation of the sciatic nerve and the wound bed in the
injured skin, in which the administration of conditioned
medium derived from DFX-preconditioned AD-MSCs ex-
hibited a superior effect compared to the administration of
conditioned medium derived from non-preconditioned
cells, suggesting that preconditioned AD-MSCs may
support the angiogenic process better than non-
preconditioned cells. Compared with different precon-
ditioning stimulus, DFX has the advantage that this
drug has been used in humans for three decades with
no toxic effects to treat iron overload diseases [88],
and it has been previously demonstrated that due to
its small size, it could be completely removed from
the final product in the concentration steps [30].
The content and relevance of the factors present in
the AD-MSC-conditioned medium is still under study.
Our proteomic analysis identified 569 factors, which are
mostly shared by both conditioned media (Fig. 9a, b).
This fact could explain the similarities in the therapeutic
effects achieved by both conditioned media. Among these
569 factors, 17 were significantly overrepresented in the
conditioned medium derived from DFX-preconditioned
AD-MSCs, including potent angiogenic factors such as
VEGF-α and NDNF, which could explain the superiority
of this conditioned medium to potentiate the angiogenesis
process compared to conditioned medium derived from
non-preconditioned AD-MSCs. Other proteins highly rep-
resented, such as stanniocalcin-1 and VEGF-α (f) (a 111
amino acid fragment, H0YBI8 in UniProt), also constitutes
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proteins with an established role in angiogenic sprouting
and putative VEGF receptor ligand, respectively [89, 90].
Selective neutralization of individual factors as well as
combinations of factors will allow the definition of the
essential components required to induce the therapeutic
effects in DPN treatment. If specific paracrine MSC-
derived factors can be identified, then protein-based
therapy might be used.
Conclusions
This research indicates that the cocktail of bioactive media-
tors present in the conditioned medium of AD-MSCs could
convert a neurodestructive/pro-inflammatory microenvir-
onment to a neuroprotective/anti-inflammatory one. Thus,
using a conditioned medium of MSCs may be an excellent
and novel therapeutic method to reverse the initial stages
of DPN, avoiding the generation of FU and reducing the
risk of lower limb amputation.
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50 μl of conditioned medium derived from 1 × 106 DFX-preconditioned
AD-MSCs. The second group was treated with intravenous administration
of 50 μl of conditioned medium derived from 1 × 106 non-
preconditioned AD-MSCs, while the third group received intravenous ad-
ministration of 50 μl of vehicle. Conditioned medium or vehicle adminis-
trations were repeated every two weeks for a total of four
administrations. An additional group of normal non-diabetic (db/+) mice
treated with vehicle was used as a healthy control. At 18, 22 and 26
weeks of age, functional parameters characteristic of DPN including
hypoalgesia to thermal and mechanical stimulation and motor nerve
conduction velocity were evaluated. At 26 weeks of age, some animals of
each group were euthanized and several structural markers characteristic
of DPN including intraepidermal nerve fiber density, ultrastructural ana-
lysis of nerve fibers, apoptosis of neurons and Schwann cells, blood flow
to nerve fibers and infiltration of T lymphocytes and macrophages were
evaluated. At 26 weeks of age the remaining animals were anesthetized
and a wound was made in the dorsal surface of both feet. Wound clos-
ure was evaluated daily while determination of mRNA levels of angio-
genic, and matrix-related factors and determination of wound re-
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Additional file 2 : Supplementary Figure 2: Plasma glucose level and
body weight is not altered by conditioned medium administration. (A)
Blood glucose levels were evaluated every two weeks using a
glucometer. (B) Body weight was evaluated every two weeks. Data are
presented as mean ± SEM (n = 20 per experimental group, two-way
ANOVA with Bonferroni post-test).
Additional file 3 : Supplementary Figure 3: Electrophysiological
impairment of sciatic nerve is partially rescued by conditioned medium
administration. (A) Quantification of CMAP amplitude in non-diabetic and
diabetic mice treated with vehicle, conditioned medium derived from
non-preconditioned AD-MSCs, or conditioned medium derived from
DFX-preconditioned AD-MSCs measured at 22 and 26 weeks of age. (B)
Quantification of CMAP latency-to-peak of the same animals of Fig. A
measured at 22 and 26 weeks of age. Data are presented as mean ±
S.E.M. (n ≥ 8, one-way ANOVA with Tukey post-test, * p < 0.05).
Additional file 4 : Supplementary Figure 4: Mitochondrial area and
density in sciatic nerves is not affected by diabetic condition. (A)
Representative electron microscopy images of ultrathin sections of sciatic
nerves, showing mitochondria (arrows) structure and distribution in
myelinated and unmyelinated fibers. (B) Quantification of mitochondria
density and area in myelinated and unmyelinated fibers. Data are
presented as mean ± S.E.M. (n = 6, one way ANOVA with Tukey post-test).
Abbreviations
α-MEM: Minimal essential medium alpha; AD-MSCs: Adipose tissue-derived
mesenchymal stem cells; BDNF: Brain-derived neurotrophic factor;
CD3: Cluster of differentiation 3; CD11b: Cluster of differentiation 11b;
CM: Conditioned medium; CMAP: Compound motor action potential;
DAPI: 4′,6-Diamidino-2-phenylindole; DFX: Deferoxamine; DM: Diabetes
mellitus; DPN: Diabetic polyneuropathy; DRG: Dorsal root ganglia; FBS: Fetal
bovine serum; FU: Foot ulcers; HIF1α: Hypoxia-inducible factor 1 alpha;
IENF: Intraepidermal nerve fibers; IGF-1: Insulin-like growth factor-1; IL-
1β: Interleukin 1 beta; LC-MS: Liquid chromatography–mass spectrometry;
MSCs: Mesenchymal stem cells; NDNF: Neuron derived neurotrophic factor;
NGF: Neural growth factor; NT3: Neurotrophin 3; PARP: Poly ADP-ribose poly-
merase; PBS: Phosphate-buffered saline; PDGF: Platelet-derived growth factor;
PGP-9.5: Protein gene product 9.5; ROS: Reactive oxygen species; TNF-
α: Tumor necrosis factor alpha; TUNEL: Terminal deoxynucleotidyl transferase
dUTP nick end labeling; VEGF-α: Vascular endothelial growth factor alpha
Acknowledgments
The authors thank Dr. Anne Bliss for English editing of the manuscript.
Authors’ contributions
CDG: Conception and design, provision of study material, collection of data,
data analysis, manuscript writing and final approval of the manuscript. DC:
Collection of data, data analysis and final approval of the manuscript. DD:
Collection of data, data analysis and final approval of the manuscript. CC:
Collection of data, data analysis and final approval of the manuscript. DS:
Collection of data, data analysis and final approval of the manuscript. LLG:
Collection of data, data analysis and final approval of the manuscript CA:
Collection of data, data analysis and final approval of the manuscript. MC:
Collection of data, data analysis and final approval of the manuscript. DC:
Collection of data, data analysis and final approval of the manuscript. CG:
Collection of data, data analysis and final approval of the manuscript. MG:
Collection of data, data analysis, financial support and final approval of the
manuscript. VAT: Collection of data, data analysis and final approval of the
manuscript. VMC: Collection of data, data analysis and final approval of the
manuscript. ME: Concepcion and design, data analysis and final approval of
the manuscript. FE: Conception and design, financial support, data analysis,
manuscript writing and final approval of the manuscript.
Funding
This work was supported by FONDECYT #1170712 to Fernando Ezquer.
Availability of data and materials
All data generated or analyzed during this study are included in this
published article and its supplementary information file.
Ethics approval and consent to participate
Human AD-MSCs were isolated from subcutaneous adipose tissue (abdom-
inal liposuction), after written informed consent. All protocols were approved
by the Ethics Committee of School of Medicine, Clínica Alemana-Universidad
del Desarrollo (Protocol 2015-40).
All animal procedures were approved by the Committee for Experiments
with Laboratory Animals of the School of Medicine, Universidad del




The authors declare they have no competing interests.
Gregorio et al. Stem Cell Research & Therapy          (2020) 11:168 Page 19 of 21
Author details
1Center for Regenerative Medicine, School of Medicine Clínica
Alemana-Universidad del Desarrollo, Av. Las Condes 12438, Lo Barnechea,
Santiago, Chile. 2Institute of Histology and Embryology of Mendoza
(IHEM-CONICET), School of Medicine, Universidad Nacional de Cuyo,
Mendoza, Argentina. 3Department of Neurology & Neurosurgery, Hospital
José Joaquín Aguirre, Universidad de Chile, Santiago, Chile. 4Institute of
Anatomy, Histology and Pathology, Universidad Austral de Chile, Valdivia,
Chile. 5Research Center for Advanced Biochemistry and Molecular Biology,
Department of Experimental and Clinical Medicine, University of Catanzaro,
Catanzaro, Italy. 6Advanced Center for Chronic Diseases-ACCDiS, Faculty of
Chemical and Pharmaceutical Sciences, Universidad de Chile, Santiago, Chile.
Received: 13 January 2020 Revised: 31 March 2020
Accepted: 15 April 2020
References
1. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, et al. Diabetic
neuropathies: a statement by the American Diabetes Association. Diabetes
Care. 2005;28:956–62.
2. Argoff CE, Cole BE, Fishbain DA, Irving GA. Diabetic peripheral neuropathic
pain: clinical and quality-of-life issues. Mayo Clin Proc. 2006;81:S3–11.
3. Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al.
Diabetic neuropathies: update on definitions, diagnostic criteria, estimation
of severity, and treatments. Diabetes Care. 2010;33:2285–93.
4. Miyajima S, Shirai A, Yamamoto S, Okada N, Matsushita T. Risk factors for
major limb amputations in diabetic foot gangrene patients. Diabetes Res
Clin Pract. 2006;71:272–9.
5. Varkonyi T, Kempler P. Diabetic neuropathy: new strategies for treatment.
Diabetes Obes Metab. 2008;10:99–108.
6. Feldman EL, Nave KA, Jensen TS, Bennett DLH. New horizons in diabetic
neuropathy: mechanisms, bioenergetics, and pain. Neuron. 2017;93:1296–313.
7. Figueroa-Romero C, Sadidi M, Feldman EL. Mechanisms of disease: the
oxidative stress theory of diabetic neuropathy. Rev Endocr Metab Disord.
2008;9:301–14.
8. Dewanjee S, Das S, Das AK, Bhattacharjee N, Dihingia A, Dua TK, et al.
Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic
targets. Eur J Pharmacol. 2018;833:472–523.
9. Thakur P, Kumar A, Kumar A. Targeting oxidative stress through antioxidants
in diabetes mellitus. J Drug Target. 2018;26:766–76.
10. Zhou J, Zhou S. Inflammation: therapeutic targets for diabetic neuropathy.
Mol Neurobiol. 2014;49:536–46.
11. Li R, Li Y, Wu Y, Zhao Y, Chen H, Yuan Y, et al. Heparin-Poloxamer
thermosensitive hydrogel loaded with bFGF and NGF enhances peripheral
nerve regeneration in diabetic rats. Biomaterials. 2018;168:24–37.
12. Schratzberger P, Walter DH, Rittig K, Bahlmann FH, Pola R, Curry C, et al.
Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin
Invest. 2001;107:1083–92.
13. Obrosova IG. Diabetic painful and insensate neuropathy: pathogenesis and
potential treatments. Neurotherapeutics. 2009;6:638–47.
14. Mizukami H, Yagihashi S. Exploring a new therapy for diabetic
polyneuropathy - the application of stem cell transplantation. Front
Endocrinol. 2014;5:45.
15. Kim WS, Park BS, Kim HK, Park JS, Kim KJ, Choi JS, et al. Evidence supporting
antioxidant action of adipose-derived stem cells: protection of human
dermal fibroblasts from oxidative stress. J Dermatol Sci. 2008;49:133–42.
16. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell
Biochem. 2006;98:1076–84.
17. Prockop DJ, Oh JY. Mesenchymal stem/stromal cells (MSCs): role as
guardians of inflammation. Mol Ther. 2012;20:14–20.
18. Kim BJ, Jin HK, Bae JS. Bone marrow-derived mesenchymal stem cells
improve the functioning of neurotrophic factors in a mouse model of
diabetic neuropathy. Lab Anim Res. 2011;27:171–6.
19. Naruse K, Sato J, Funakubo M, Hata M, Nakamura N, Kobayashi Y, et al.
Transplantation of bone marrow-derived mononuclear cells improves
mechanical hyperalgesia, cold allodynia and nerve function in diabetic
neuropathy. PLoS One. 2011;6:e27458.
20. Shibata T, Naruse K, Kamiya H, Kozakae M, Kondo M, Yasuda Y, et al.
Transplantation of bone marrow-derived mesenchymal stem cells improves
diabetic polyneuropathy in rats. Diabetes. 2008;57:3099–107.
21. Han JW, Choi D, Lee MY, Huh YH, Yoon YS. Bone marrow-derived
mesenchymal stem cells improve diabetic neuropathy by direct modulation
of both angiogenesis and myelination in peripheral nerves. Cell Transplant.
2016;25:313–26.
22. Kunter U, Rong S, Boor P, Eitner F, Muller-Newen G, Djuric Z, et al.
Mesenchymal stem cells prevent progressive experimental renal failure but
maldifferentiate into glomerular adipocytes. J Am Soc Nephrol. 2007;18:
1754–64.
23. Griffin MD, Ryan AE, Alagesan S, Lohan P, Treacy O, Ritter T. Anti-donor
immune responses elicited by allogeneic mesenchymal stem cells: what
have we learned so far? Immunol Cell Biol. 2013;91:40–51.
24. Eggenhofer E, Benseler V, Kroemer A, Popp FC, Geissler EK, Schlitt HJ, et al.
Mesenchymal stem cells are short-lived and do not migrate beyond the
lungs after intravenous infusion. Front Immunol. 2012;3:297.
25. Kato J, Kamiya H, Himeno T, Shibata T, Kondo M, Okawa T, et al.
Mesenchymal stem cells ameliorate impaired wound healing through
enhancing keratinocyte functions in diabetic foot ulcerations on the plantar
skin of rats. J Diabetes Complicat. 2014;28:588–95.
26. Zhao QS, Xia N, Zhao N, Li M, Bi CL, Zhu Q, et al. Localization of human
mesenchymal stem cells from umbilical cord blood and their role in repair
of diabetic foot ulcers in rats. Int J Biol Sci. 2013;10:80–9.
27. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9:11–5.
28. Yu SP, Wei Z, Wei L. Preconditioning strategy in stem cell transplantation
therapy. Transl Stroke Res. 2013;4:76–88.
29. Quintanilla ME, Ezquer F, Morales P, Santapau D, Berrios-Carcamo P, Ezquer
M, et al. Intranasal mesenchymal stem cell secretome administration
markedly inhibits alcohol and nicotine self-administration and blocks
relapse-intake: mechanism and translational options. Stem Cell Res Ther.
2019;10:205.
30. Oses C, Olivares B, Ezquer M, Acosta C, Bosch P, Donoso M, et al.
Preconditioning of adipose tissue-derived mesenchymal stem cells with
deferoxamine increases the production of pro-angiogenic, neuroprotective
and anti-inflammatory factors: potential application in the treatment of
diabetic neuropathy. PLoS One. 2017;12:e0178011.
31. Sullivan KA, Hayes JM, Wiggin TD, Backus C, Su Oh S, Lentz SI, et al. Mouse
models of diabetic neuropathy. Neurobiol Dis. 2007;28:276–85.
32. O'Brien PD, Sakowski SA, Feldman EL. Mouse models of diabetic
neuropathy. ILAR J. 2014;54:259–72.
33. De Gregorio C, Contador D, Campero M, Ezquer M, Ezquer F.
Characterization of diabetic neuropathy progression in a mouse model of
type 2 diabetes mellitus. Biol Open. 2018;7(9).
34. Evangelista AF, Vannier-Santos MA, de Assis Silva GS, Silva DN, Juiz PJL,
Nonaka CKV, et al. Bone marrow-derived mesenchymal stem/stromal cells
reverse the sensorial diabetic neuropathy via modulation of spinal
neuroinflammatory cascades. J Neuroinflammation. 2018;15:189.
35. Ferreira TA, Blackman AV, Oyrer J, Jayabal S, Chung AJ, Watt AJ, et al.
Neuronal morphometry directly from bitmap images. Nat Methods. 2014;11:
982–4.
36. Lau TW, Sahota DS, Lau CH, Chan CM, Lam FC, Ho YY, et al. An in vivo
investigation on the wound-healing effect of two medicinal herbs using an
animal model with foot ulcer. Eur Surg Res. 2008;41:15–23.
37. Shi R, Jin Y, Cao C, Han S, Shao X, Meng L, et al. Localization of human
adipose-derived stem cells and their effect in repair of diabetic foot ulcers
in rats. Stem Cell Res Ther. 2016;7:155.
38. Cox J, Hein MY, Luber CA, Paron I, Nagaraj N, Mann M. Accurate proteome-
wide label-free quantification by delayed normalization and maximal
peptide ratio extraction, termed MaxLFQ. Mol Cell Proteomics. 2014;13:
2513–26.
39. Rudolph J, Cox J. A network module for the Perseus software for
computational proteomics facilitates proteome interaction graph analysis. J
Proteome Res. 2019;18:2052–64.
40. Croft D, O'Kelly G, Wu G, Haw R, Gillespie M, Matthews L, et al. Reactome: a
database of reactions, pathways and biological processes. Nucleic Acids Res.
2011;39:691–7.
41. Ashburner M, Ball C, Blake J, Botstein D, Butler H, Cherry M, et al. Gene
Ontology: tool for the unification of biology. Nat Genet. 2000;25:25–9.
42. Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes.
Nucleic Acids Res. 2000;28:27–30.
43. Slenter D, Kutmon M, Haspers K, Riutta A, Windsor J, Nunes N, et al.
WikiPathways: a multifaceted pathway database bridging metabolomics to
other omics research. Nucleic Acids Res. 2018;46:661–7.
Gregorio et al. Stem Cell Research & Therapy          (2020) 11:168 Page 20 of 21
44. Kuleshov M, Jones M, Roullard A, Fernadez N, Duan Q, Wang Z, et al.
Enrichr: a comprehensive gene set enrichment analysis web server 2016
update. Nucleic Acids Res. 2016;44:90–7.
45. Franz M, Rodriguez H, Lopes C, Zuberi K, Montojo J, Bader G, et al.
GeneMANIA update 2018. Nucleic Acids Res. 2018;46:60–4.
46. Quattrini C, Tavakoli M, Jeziorska M, Kallinikos P, Tesfaye S, Finnigan J, et al.
Surrogate markers of small fiber damage in human diabetic neuropathy.
Diabetes. 2007;56:2148–54.
47. Campero M, Ezquer M, Ezquer F. Nerve excitability and structural changes in
myelinated axons from diabetic mice. Exp Clin Endocrinol Diabetes. 2015;
123:485–91.
48. Almohaimeed H, Amin H, Adb El-Azid G, Saleh H. Arabic gum Acacia in
combination with metformin and vitamin B12 improves diabetic peripheral
neuropathy in rats: ultrastructural histopathological study. J Interdiscip
Histopatol. 2019;7:1–9.
49. Gilloteaux J, Subramanian K, Solomon N, Nicaise C. The leptin receptor
mutation of the obese Zucker rat causes sciatic nerve demyelination with a
centripetal pattern defect. Ultrastruct Pathol. 2018;42:377–408.
50. Hayden M, Grand D, Aroor A, DeMarco V. Ultrastructural remodeling of the
neurovascular unit in the female diabetic db/db model—part III:
oligodendrocyte and myelin. Neuroglia. 2018;1:351–64.
51. Barrientos SA, Martinez NW, Yoo S, Jara JS, Zamorano S, Hetz C, et al. Axonal
degeneration is mediated by the mitochondrial permeability transition pore.
J Neurosci. 2011;31:966–78.
52. Sugimura K, Dyck PJ. Sural nerve myelin thickness and axis cylinder caliber
in human diabetes. Neurology. 1981;31:1087–91.
53. Nowicki M, Kosacka J, Serke H, Bluher M, Spanel-Borowski K. Altered sciatic
nerve fiber morphology and endoneural microvessels in mouse models
relevant for obesity, peripheral diabetic polyneuropathy, and the metabolic
syndrome. J Neurosci Res. 2012;90:122–31.
54. Cermenati G, Audano M, Giatti S, Carozzi V, Porretta-Serapiglia C, Pettinato E,
et al. Lack of sterol regulatory element binding factor-1c imposes glial fatty
acid utilization leading to peripheral neuropathy. Cell Metab. 2015;21:571–83.
55. Sango K, Mizukami H, Horie H, Yagihashi S. Impaired axonal regeneration in
diabetes. Perspective on the underlying mechanism from in vivo and
in vitro experimental studies. Front Endocrinol. 2017;8:12.
56. Britland ST, Young RJ, Sharma AK, Clarke BF. Association of painful and
painless diabetic polyneuropathy with different patterns of nerve fiber
degeneration and regeneration. Diabetes. 1990;39:898–908.
57. Melli G, Hoke A. Dorsal root ganglia sensory neuronal cultures: a tool for
drug discovery for peripheral neuropathies. Expert Opin Drug Discovery.
2009;4:1035–45.
58. Sango K, Saito H, Takano M, Tokashiki A, Inoue S, Horie H. Cultured adult
animal neurons and Schwann cells give us new insights into diabetic
neuropathy. Curr Diabetes Rev. 2006;2:169–83.
59. Coppey LJ, Gellett JS, Davidson EP, Dunlap JA, Lund DD, Yorek MA. Effect of
antioxidant treatment of streptozotocin-induced diabetic rats on
endoneurial blood flow, motor nerve conduction velocity, and vascular
reactivity of epineurial arterioles of the sciatic nerve. Diabetes. 2001;50:
1927–37.
60. Vincent AM, Callaghan BC, Smith AL, Feldman EL. Diabetic neuropathy:
cellular mechanisms as therapeutic targets. Nat Rev Neurol. 2011;7:573–83.
61. Boucek P. Advanced diabetic neuropathy: a point of no return? Rev Diabet
Stud. 2006;3:143–50.
62. da Silva ML, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in
virtually all post-natal organs and tissues. J Cell Sci. 2006;119:2204–13.
63. Lee HC, An SG, Lee HW, Park JS, Cha KS, Hong TJ, et al. Safety and effect of
adipose tissue-derived stem cell implantation in patients with critical limb
ischemia: a pilot study. Circ J. 2012;76:1750–60.
64. Plock JA, Schnider JT, Schweizer R, Gorantla VS. Are cultured mesenchymal
stromal cells an option for immunomodulation in transplantation? Front
Immunol. 2013;4:41.
65. Salgado AJ, Reis RL, Sousa NJ, Gimble JM. Adipose tissue derived stem cells
secretome: soluble factors and their roles in regenerative medicine. Curr
Stem Cell Res Ther. 2010;5:103–10.
66. Gama KB, Santos DS, Evangelista AF, Silva DN, de Alcantara AC, Dos Santos
RR, et al. Conditioned medium of bone marrow-derived mesenchymal
stromal cells as a therapeutic approach to neuropathic pain: a preclinical
evaluation. Stem Cells Int. 2018;2018:8179013.
67. Cantinieaux D, Quertainmont R, Blacher S, Rossi L, Wanet T, Noel A, et al.
Conditioned medium from bone marrow-derived mesenchymal stem cells
improves recovery after spinal cord injury in rats: an original strategy to
avoid cell transplantation. PLoS One. 2013;8:e69515.
68. Cizkova D, Cubinkova V, Smolek T, Murgoci AN, Danko J, Vdoviakova K, et al.
Localized intrathecal delivery of mesenchymal stromal cells conditioned
medium improves functional recovery in a rat model of spinal cord injury.
Int J Mol Sci. 2018;19(3). https://doi.org/10.3390/ijms19030870.
69. Brini AT, Amodeo G, Ferreira LM, Milani A, Niada S, Moschetti G, et al.
Therapeutic effect of human adipose-derived stem cells and their
secretome in experimental diabetic pain. Sci Rep. 2017;7:9904.
70. Liu L, Gao J, Yuan Y, Chang Q, Liao Y, Lu F. Hypoxia preconditioned human
adipose derived mesenchymal stem cells enhance angiogenic potential via
secretion of increased VEGF and bFGF. Cell Biol Int. 2013;37:551–60.
71. Abraira VE, Ginty DD. The sensory neurons of touch. Neuron. 2013;79:618–
39.
72. Shun CT, Chang YC, Wu HP, Hsieh SC, Lin WM, Lin YH, et al. Skin
denervation in type 2 diabetes: correlations with diabetic duration and
functional impairments. Brain. 2004;127:1593–605.
73. Behse F, Buchthal F, Carlsen F. Nerve biopsy and conduction studies in
diabetic neuropathy. J Neurol Neurosurg Psychiatry. 1977;40:1072–82.
74. Trevillion L, Howells J, Bostock H, Burke D. Properties of low-threshold
motor axons in the human median nerve. J Physiol. 2010;588:2503–15.
75. Bostock H, Campero M, Serra J, Ochoa J. Velocity recovery cycles of C fibres
innervating human skin. J Physiol. 2003;553:649–63.
76. Schmeichel AM, Schmelzer JD, Low PA. Oxidative injury and apoptosis of
dorsal root ganglion neurons in chronic experimental diabetic neuropathy.
Diabetes. 2003;52:165–71.
77. Tosaki T, Kamiya H, Yasuda Y, Naruse K, Kato K, Kozakae M, et al. Reduced
NGF secretion by Schwann cells under the high glucose condition
decreases neurite outgrowth of DRG neurons. Exp Neurol. 2008;213:381–7.
78. Schaper NC, Huijberts M, Pickwell K. Neurovascular control and neurogenic
inflammation in diabetes. Diabetes Metab Res Rev. 2008;24:S40–4.
79. Watkins LR, Maier SF, Goehler LE. Immune activation: the role of pro-
inflammatory cytokines in inflammation, illness responses and pathological
pain states. Pain. 1995;63:289–302.
80. Omi M, Hata M, Nakamura N, Miyabe M, Kobayashi Y, Kamiya H, et al.
Transplantation of dental pulp stem cells suppressed inflammation in sciatic
nerves by promoting macrophage polarization towards anti-inflammation
phenotypes and ameliorated diabetic polyneuropathy. J Diab Invest. 2016;7:
485–96.
81. Waterman RS, Morgenweck J, Nossaman BD, Scandurro AE, Scandurro SA,
Betancourt AM. Anti-inflammatory mesenchymal stem cells (MSC2)
attenuate symptoms of painful diabetic peripheral neuropathy. Stem Cells
Transl Med. 2012;1:557–65.
82. Wang XT, McKeever CC, Vonu P, Patterson C, Liu PY. Dynamic histological
events and molecular changes in excisional wound healing of diabetic DB/
DB mice. J Surg Res. 2019;238:186–97.
83. Falanga V. Wound healing and its impairment in the diabetic foot. Lancet.
2005;366:1736–43.
84. Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and
regeneration. Nature. 2008;453:314–21.
85. Wan J, Xia L, Liang W, Liu Y, Cai Q. Transplantation of bone marrow-derived
mesenchymal stem cells promotes delayed wound healing in diabetic rats.
J Diab Res. 2013;2013:647107.
86. Kuo YR, Wang CT, Cheng JT, Kao GS, Chiang YC, Wang CJ. Adipose-derived
stem cells accelerate diabetic wound healing through the induction of
autocrine and paracrine effects. Cell Transplant. 2016;25:71–81.
87. Cao Y, Gang X, Sun C, Wang G. Mesenchymal stem cells improve healing of
diabetic foot ulcer. J Diab Res. 2017;2017:9328347.
88. Howland MA. Risks of parenteral deferoxamine for acute iron poisoning. J
Toxicol Clin Toxicol. 1996;34:491–7.
89. Law A, Wong C. Stanniocalcin-1 and -2 promote angiogenic sprouting in
HUVECs via VEGF/VEGFR2 and angiopoietin signaling pathways. Mol Cell
Endocrinol. 2013;374:73–81.
90. UniProt C. UniProt: a hub for protein information. Nucleic Acids Res. 2015;
43:204–12.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Gregorio et al. Stem Cell Research & Therapy          (2020) 11:168 Page 21 of 21
